82 A new artificial intelligence model has demonstrated exceptional accuracy in detecting melanoma, surpassing several existing approaches and offering hope for earlier and more reliable diagnosis of the deadliest form of skin cancer. The model, known as MCADT, combines convolutional neural networks with advanced image augmentation techniques to identify melanoma with an accuracy of 93.43 percent. This outperforms many previous systems and even experienced dermatologists, according to a study published in the International Journal of Imaging Systems and Technology. Melanoma accounts for a small proportion of skin cancer cases but is responsible for the majority of skin cancer-related deaths. Early detection is critical to improving survival rates, but diagnosis can be challenging due to the subtle and diverse features of melanoma in skin lesions. Traditional clinical assessments are susceptible to human error and may be inconsistent, especially in under-resourced settings. The MCADT model addresses these limitations by training on a highly curated and augmented dataset of over 27,000 images derived from the widely used HAM10000 collection. Researchers applied five specific augmentation techniques, including horizontal flipping, cropping, greyscale conversion, Gaussian blurring, and random perspective transformation, to compensate for imbalances and deficiencies in existing datasets. This method not only enhanced the model’s generalisability but also enabled it to perform well across various lesion types and imaging conditions. The system was trained on standardised, pre-processed images resized to 224 by 224 pixels and optimised using a range of techniques to avoid overfitting. These included batch normalisation, dropout layers, and the use of the Adam optimiser for stochastic learning. Testing revealed a sensitivity rate of 99.74 percent, meaning the model accurately identified nearly all true cases of melanoma, while maintaining a specificity rate of 88.45 percent, reducing the likelihood of false positives. These figures suggest the system is especially effective in correctly flagging early signs of melanoma, which is essential for timely intervention. The research also included ablation studies to fine-tune the model’s performance by adjusting parameters such as learning rates, kernel sizes, and pooling methods. The best results were achieved using a ReLU activation function, a learning rate of 0.001, and 50 training epochs. When compared with other models, including ResNet, DenseNet, and AlexNet, MCADT consistently delivered superior performance. Despite the promising results, the study acknowledges limitations. The model was tested primarily on the HAM10000 dataset and not validated across multiple diverse clinical settings. The authors suggest that future developments could include expanding to other datasets, incorporating multimodal inputs such as patient demographics and genetic data, and moving towards real-time clinical integration. The implications for healthcare are significant. The model has the potential to assist clinicians in rural or underserved regions where specialist dermatological services are scarce. It could also reduce costs associated with biopsies and lab-based diagnostics by providing reliable preliminary assessments through automated imaging analysis.